These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 116629)

  • 1. [Etiologic therapy of Chagas' disease].
    Boainain E; Rassi A
    Arq Bras Cardiol; 1979 Jun; 32(6):395-9. PubMed ID: 116629
    [No Abstract]   [Full Text] [Related]  

  • 2. [Etiological treatment of Chagas' disease].
    Rassi A
    Arq Bras Cardiol; 1982 Apr; 38(4):277-81. PubMed ID: 6820273
    [No Abstract]   [Full Text] [Related]  

  • 3. [Treatment of Chagas' disease].
    Apt W
    Rev Med Chil; 1985 Feb; 113(2):162-6. PubMed ID: 3936147
    [No Abstract]   [Full Text] [Related]  

  • 4. [Possibility of treatment in Chagas' disease].
    Prata A
    AMB Rev Assoc Med Bras; 1978 Apr; 24(4):140-2. PubMed ID: 98813
    [No Abstract]   [Full Text] [Related]  

  • 5. Suppression of antibody dependent cytotoxicity to Trypanosoma cruzi in chronic chagasic mice after treatment with nifurtimox.
    Chambó JG; Cabeza Meckert PM; Laguens RP
    Medicina (B Aires); 1988; 48(1):49-53. PubMed ID: 3146009
    [No Abstract]   [Full Text] [Related]  

  • 6. Antitrypanosomal therapy for chronic Chagas' disease.
    Bern C
    N Engl J Med; 2011 Jun; 364(26):2527-34. PubMed ID: 21714649
    [No Abstract]   [Full Text] [Related]  

  • 7. [Evaluation of complement mediated lysis technic in patients with chronic Chagas' disease treated with trypanocidal drugs].
    Levy AM; Pereira VL; Boainain E
    Rev Inst Med Trop Sao Paulo; 1988; 30(1):32-9. PubMed ID: 3146793
    [No Abstract]   [Full Text] [Related]  

  • 8. [Longitudinal study of the persistence of the therapeutic action of nifurtimox and benznidazole in patients with chronic chagas infection].
    Schenone H; Rojas A; Alfaro E; Concha L; Aranda R
    Bol Chil Parasitol; 1981; 36(3-4):59-62. PubMed ID: 6812600
    [No Abstract]   [Full Text] [Related]  

  • 9. [Congenital Chagas' disease. Report of a case with cerebral palsy].
    Vieira GO; Maguire J; Bittencourt AL; Fontes JA
    Rev Inst Med Trop Sao Paulo; 1983; 25(6):305-9. PubMed ID: 6424220
    [No Abstract]   [Full Text] [Related]  

  • 10. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease.
    Filardi LS; Brener Z
    Trans R Soc Trop Med Hyg; 1987; 81(5):755-9. PubMed ID: 3130683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of the efficacy of nifurtimox in chronic human chagasic infection by using xenodiagnosis (author's transl)].
    Cerisola JA; Neves da Silva N; Prata A; Schenone H; Rohwedder R
    Bol Chil Parasitol; 1977; 32(3-4):51-62. PubMed ID: 416834
    [No Abstract]   [Full Text] [Related]  

  • 12. Recognizing and meeting the challenge of Chagas disease in the USA.
    Bowling J; Walter EA
    Expert Rev Anti Infect Ther; 2009 Dec; 7(10):1223-34. PubMed ID: 19968514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-Nitro-2-furyl derivative actives against Trypanosoma cruzi: preliminary in vivo studies.
    Cabrera E; Murguiondo MG; Arias MG; Arredondo C; Pintos C; Aguirre G; Fernández M; Basmadjián Y; Rosa R; Pacheco JP; Raymondo S; Di Maio R; González M; Cerecetto H
    Eur J Med Chem; 2009 Oct; 44(10):3909-14. PubMed ID: 19446929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of chemotherapy with benznidazole and nifurtimox in mice infected with Trypanosoma cruzi strains of different types.
    Andrade SG; Magalhães JB; Pontes AL
    Bull World Health Organ; 1985; 63(4):721-6. PubMed ID: 3936634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Nifurtimox, a bright future for treatment of Chagas disease].
    Wolf A; Boulliat C; Coillot C; Rouault M; Gaillard K; Beranger C; Oliver M
    Med Trop (Mars); 2011 Apr; 71(2):131-3. PubMed ID: 21695868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of Chagas' disease with nifurtimox during the first months of life].
    Moya PR; Paolasso RD; Blanco S; Lapasset M; Sanmartino C; Basso B; Moretti E; Cura D
    Medicina (B Aires); 1985; 45(5):553-8. PubMed ID: 3939553
    [No Abstract]   [Full Text] [Related]  

  • 17. Nifurtimox chemotherapy: collateral effects in treated Trypanosoma cruzi infected patients.
    Murcia L; Carrilero B; Albajar Viñas P; Segovia M
    Rev Esp Quimioter; 2012 Mar; 25(1):74-5. PubMed ID: 22488545
    [No Abstract]   [Full Text] [Related]  

  • 18. [Isoenzymatic pattern of Trypanosoma cruzi Y strain after specific chemotherapy].
    Silva RC; Santiago CM; Pontes AL; Andrade SG
    Mem Inst Oswaldo Cruz; 1989; 84(1):81-6. PubMed ID: 2108307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chronic Chagas' disease: effects of treatment nn the levels of antibodies to crude and partially purified Trypanosoma cruzi antigens].
    Moretti E; Cervetta L; Basso B; Castro I; Santamarina N
    Bol Chil Parasitol; 1998; 53(1-2):3-9. PubMed ID: 9830716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell-mediated immunity in Chagas' disease: Alterations induced by treatment with a trypanocidal drug (nifurtimox).
    Lelchuk R; Cardoni RL; Fuks AS
    Clin Exp Immunol; 1977 Dec; 30(3):434-8. PubMed ID: 414867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.